SRTA (Strata Critical Medical, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SRTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Amir Cohen | Chief Accounting Officer | F | — | — |
| 2026-09-10 | Melissa M. Tomkiel | Co-CEO and General Counsel | F | — | — |
| 2026-09-10 | William A. Heyburn | Co-CEO and CFO | F | — | — |
| 2026-09-10 | Scott M Wunsch | CEO, Logistics | F | — | — |
| 2026-09-10 | Louis R. Verdetto | CEO, Clinical Services | F | — | — |
| 2026-08-13 | Reginald Love | Director | Sell | — | — |
| 2026-08-03 | ROBERT S WIESENTHAL | Director | A | — | — |
| 2026-08-03 | ANDREW LAUCK | Director | A | — | — |
| 2026-08-03 | Scott M Wunsch | CEO, Logistics | MIXED | — | — |
| 2026-08-03 | William L. Cook III | Director | A | — | — |
| 2026-08-03 | William A. Heyburn | Co-CEO and CFO | MIXED | — | — |
| 2026-08-03 | Reginald Love | Director | A | — | — |
| 2026-08-03 | Melissa M. Tomkiel | Co-CEO and General Counsel | MIXED | — | — |
| 2026-08-03 | EDWARD M PHILIP | Director | A | — | — |
| 2026-08-03 | Amir Cohen | Chief Accounting Officer | MIXED | — | — |
| 2026-06-18 | Melissa M. Tomkiel | Co-CEO and General Counsel | F | — | — |
| 2026-06-18 | William A. Heyburn | Co-CEO and CFO | F | — | — |
| 2026-06-18 | Scott M Wunsch | CEO, Logistics | F | — | — |
| 2026-06-18 | Amir Cohen | Chief Accounting Officer | F | — | — |
| 2026-06-10 | Amir Cohen | Chief Accounting Officer | Sell | — | — |
| 2026-06-10 | Melissa M. Tomkiel | Co-CEO and General Counsel | Sell | — | — |
| 2026-06-10 | William A. Heyburn | Co-CEO and CFO | Sell | — | — |
| 2026-06-10 | Scott M Wunsch | CEO, Logistics | Sell | — | — |
| 2026-05-26 | Amir Cohen | Chief Accounting Officer | Sell | — | — |
| 2026-05-13 | Amir Cohen | Chief Accounting Officer | Sell | — | — |
| 2026-05-08 | Velibor Krstic | 10%+ Owner | H | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,325,896 | — |
| — | Co-CEO and General Counsel | 2,066,617 | — |
| — | Co-CEO and CFO | 1,678,348 | — |
| — | CEO, Clinical Services | 1,260,328 | — |
| — | CEO, Logistics | 1,046,030 | — |
| — | Director | 265,078 | — |
| — | Chief Accounting Officer | 177,154 | — |
| — | Director | 170,902 | — |
| — | Director | 146,481 | — |
| — | Director | 97,671 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRTA quote page; the site-wide leaderboard is on the insider transactions hub.